Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study

Stock Information for Evoke Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Evoke Pharma Inc.

Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025
Talphera Announces the Appointment of Joe Todisco to Board of Directors
CorMedix Announces Strategic Minority Investment in Talphera
Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market
Talphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial
Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.